Title | Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. |
Publication Type | Journal Article |
Year of Publication | 2011 |
Authors | Moran-Crusio, Kelly, Reavie Linsey, Shih Alan, Abdel-Wahab Omar, Ndiaye-Lobry Delphine, Lobry Camille, Figueroa Maria E., Vasanthakumar Aparna, Patel Jay, Zhao Xinyang, Perna Fabiana, Pandey Suveg, Madzo Jozef, Song Chunxiao, Dai Qing, He Chuan, Ibrahim Sherif, Beran Miloslav, Zavadil Jiri, Nimer Stephen D., Melnick Ari, Godley Lucy A., Aifantis Iannis, and Levine Ross L. |
Journal | Cancer Cell |
Volume | 20 |
Issue | 1 |
Pagination | 11-24 |
Date Published | 2011 Jul 12 |
ISSN | 1878-3686 |
Keywords | Alleles, Animals, Cell Proliferation, Cell Transformation, Neoplastic, Dioxygenases, DNA-Binding Proteins, Gene Deletion, Gene Knockout Techniques, Gene Silencing, Haploinsufficiency, Hematopoiesis, Hematopoietic Stem Cells, Humans, Leukemia, Myelomonocytic, Chronic, Mice, Myeloid Cells, Proto-Oncogene Proteins |
Abstract | <p>Somatic loss-of-function mutations in the ten-eleven translocation 2 (TET2) gene occur in a significant proportion of patients with myeloid malignancies. Although there are extensive genetic data implicating TET2 mutations in myeloid transformation, the consequences of Tet2 loss in hematopoietic development have not been delineated. We report here an animal model of conditional Tet2 loss in the hematopoietic compartment that leads to increased stem cell self-renewal in vivo as assessed by competitive transplant assays. Tet2 loss leads to a progressive enlargement of the hematopoietic stem cell compartment and eventual myeloproliferation in vivo, including splenomegaly, monocytosis, and extramedullary hematopoiesis. In addition, Tet2(+/-) mice also displayed increased stem cell self-renewal and extramedullary hematopoiesis, suggesting that Tet2 haploinsufficiency contributes to hematopoietic transformation in vivo.</p> |
DOI | 10.1016/j.ccr.2011.06.001 |
Alternate Journal | Cancer Cell |
PubMed ID | 21723200 |
PubMed Central ID | PMC3194039 |
Grant List | F31 AG039991 / AG / NIA NIH HHS / United States / HHMI / Howard Hughes Medical Institute / United States F31-AG039991 / AG / NIA NIH HHS / United States R21 CA141399 / CA / NCI NIH HHS / United States R01CA149655 / CA / NCI NIH HHS / United States CA129831 / CA / NCI NIH HHS / United States R01 CA105129-07 / CA / NCI NIH HHS / United States R01CA105129 / CA / NCI NIH HHS / United States P30 CA016087 / CA / NCI NIH HHS / United States U54 CA143798 / CA / NCI NIH HHS / United States P30 CA016087-30 / CA / NCI NIH HHS / United States 5 P30CA16087-31 / CA / NCI NIH HHS / United States R01 CA133379 / CA / NCI NIH HHS / United States R01CA133379 / CA / NCI NIH HHS / United States R01 CA129831 / CA / NCI NIH HHS / United States 5P30CA16087-31 / CA / NCI NIH HHS / United States R21CA141399 / CA / NCI NIH HHS / United States CA129831-03S1 / CA / NCI NIH HHS / United States R01 CA149655 / CA / NCI NIH HHS / United States R01 CA105129 / CA / NCI NIH HHS / United States R01 CA133379-04 / CA / NCI NIH HHS / United States 1R01CA138234-01 / CA / NCI NIH HHS / United States R01GM088847 / GM / NIGMS NIH HHS / United States R01 CA138234 / CA / NCI NIH HHS / United States U54CA143798-01 / CA / NCI NIH HHS / United States R01 GM088847 / GM / NIGMS NIH HHS / United States R01 CA149655-03 / CA / NCI NIH HHS / United States |